NCT07208162 SHARE Adaptation Intervention for African-American Families
| NCT ID | NCT07208162 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Benjamin Rose Institute on Aging |
| Condition | Mild Dementia |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-08-19 |
| Primary Completion | 2026-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2025-08-19 with a primary completion date of 2026-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project aims to culturally adapt the SHARE program for African-Americans in early-moderate stage dementia and their care partner. Upon completion of the adaptation, a pilot randomized-control trial wil be confucted to compare the adaptaed SHARE program versus usual care.
Eligibility Criteria
Inclusion Criteria: * African American dyads (both the caregivers and the care-recipient, an individual with an early-stage memory impairing condition (e.g., Alzheimer's disease, vascular dementia, cognitive impairment, etc.) * Care-recipient lives at home. * The caregiver (CG) and/or the person with dementia (PWD), or symptoms of memory loss must identify as African American. * PWD must be at least 50 years old and CGs 18 or older, * Ability to speak and read English, * Experiencing signs and symptoms of mild to moderate dementia through family caregiver report on the Dementia Severity Rating Scale and meeting the National Institute on Aging and the Alzheimer's Association clinical criteria for probable AD. Exclusion Criteria: * A mental health condition (e.g., schizophrenia, bipolar disorder, major depression) * A traumatic brain injury * Intellectual or developmental disability * Individuals experiencing extreme difficulty adjusting and coping to the diagnosis • Individuals living in an institutional setting
Contact & Investigator
Silvia Orsulic-Jeras
PRINCIPAL INVESTIGATOR
Benjamin Rose Institute on Aging
Frequently Asked Questions
Who can join the NCT07208162 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Mild Dementia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07208162 currently recruiting?
Yes, NCT07208162 is actively recruiting participants. Contact the research team at sjeras@benrose.org for enrollment information.
Where is the NCT07208162 trial being conducted?
This trial is being conducted at Cleveland, United States.
Who is sponsoring the NCT07208162 clinical trial?
NCT07208162 is sponsored by Benjamin Rose Institute on Aging. The principal investigator is Silvia Orsulic-Jeras at Benjamin Rose Institute on Aging. The trial plans to enroll 120 participants.